Compare NCA & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCA | ENTA |
|---|---|---|
| Founded | 1987 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.3M | 407.5M |
| IPO Year | N/A | 2013 |
| Metric | NCA | ENTA |
|---|---|---|
| Price | $8.79 | $14.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | 59.6K | ★ 302.8K |
| Earning Date | 01-01-0001 | 11-17-2025 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $65,324,000.00 |
| Revenue This Year | N/A | $0.99 |
| Revenue Next Year | N/A | $0.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.77 | $4.09 |
| 52 Week High | $9.12 | $15.34 |
| Indicator | NCA | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 29.66 | 72.93 |
| Support Level | $9.06 | $11.89 |
| Resistance Level | $9.15 | $14.52 |
| Average True Range (ATR) | 0.11 | 0.86 |
| MACD | -0.04 | 0.10 |
| Stochastic Oscillator | 3.92 | 95.27 |
Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.